The initiation of coverage by a reputable analyst with a Buy rating and a specific price target usually leads to increased investor interest and can positively impact the stock price in the short term. Given the direct mention and the positive nature of the coverage, it's likely to have a favorable effect on Chemomab Therapeutics' stock.